DJSP downgraded:

Maxim Group downgrades DJSP to Hold from Buy following earnings. The firm says 1Q10 operating earnings (excluding non-recurring expenses) came in $0.02 below Street expectations of $0.40, however it was the material decline in management's forward earnings guidance for 2010 which gives them pause. 2010 estimates were reportedly affected in part by slowing case volumes from a major client undergoing a data system conversion initiative. Firm says given this development happened in the first quarterly results since the company went public it raises questions among investors as to management credibility and what is the true earnings run-rate power of the business going forward.

Focus Media prelim $0.16 vs $0.15 Thomson Reuters consensus; revs $124.9 mln vs $117.42 mln Thomson Reuters consensus.

stock up in AH.

sellers are in control of this market. just moved to cash.

Briefing.com Floor Talk: How China is setting up:

Equities in China (FXI) have seen a fairly substantial selloff. Although the FXI does not mimic the Shanghai Composite Index, it still gives investors the chance to participate in Chinese companies. Recently, Beijing has sent shockwaves through the system as they try to ease lending in the Chinese real estate market. They have taken several measures over the past few months to prevent the economy from overheating. First, the government hiked short-term interest rates. Then, the Chinese government began restricting people from receiving third mortgages. Just recently, Beijing raised the banks' reserve ratio as a means of draining liquidity from the system. With inflation beginning to creep up look for an interest rate hike in the near future.

The FXI recently broke down through the neckline and gained support near 39.00. It would not be surprising to see the FXI pullback to the neckline on weak volume before eventually moving lower. The RSI is showing oversold conditions, and there appears to be a good amount of support at the current level. The upside target is at the 40.60 level. If the pullback occurs, ideally it will be on light volume as a sign of weakness. A move towards 36.00 appears likely as that would complete the measuring objective.

not behaving well here. i'm out for now, will take another look once we clear ~$11.50.

"POZN is trading up 1%, after being up over 10% in pre-market, following the company's announcement that the FDA approved Vimovo for arthritis patients at risk of developing NSAID-associated gastric ulcers. Prior to the decision, analysts had been mixed on the timing of a Vimovo approval, but expected it to be a big contributor to the company's results if approved. One of the more positive analysts, Brean Murray, raised their POZN target to $14 last week in anticipation of approval. The recent stock action also indicated a positive leaning ahead of the event, as it had more than doubled from its February lows of ~$5.50." (briefing.com)

CBAK short opp <eom>

CBAK: from briefing.com:

Reports Q2 (Mar) ($0.04), $0.04 worse than the Thomson Reuters single-analyst est of $0.00; revenues rose 0.4% year/year to $50.4 mln vs the $49.4 mln consensus. Co said, "After careful scrutiny of our performance in first half of FY 2010 we found that the business recovery in certain segments is likely to be slower than we expected. As a result, we believe it is prudent to revise our revenue guidance to approximately $220 million for FY 2010. We expect to show positive operating income and EBITDA in the second half of the fiscal year."

another rumor re: potential filing of 10k next week.